Reported to the VT Attorney General on August 17, 2026.
VT residents may qualify for compensation. Free attorney review — no obligation, no upfront cost.
Check My Rights →The following entry is drawn from a VT state breach notification filing. Amgen Inc. was responsible for safeguarding the personal data of its customers and employees. Amgen Inc. experienced a data security incident affecting an undisclosed number of individuals, exposing Full Name and Date of Birth. The precise date the breach occurred was not disclosed in the filing; the date below reflects when Amgen Inc. notified the VT Attorney General. The filing summarized the incident as follows: "Amgen Inc. stands as one of the world's leading independent biotechnology innovators, dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics to patients suffering from serious illnesses. Operating at the cutting edge of life sciences, biopharmaceuticals, and clinical research, the enterprise collects and maintains vast repositories of deeply sensitive information. This operational footprint requires the collection of extensive proprietary research data, clinical trial participant records, detailed employee and personnel files, and intricate healthcare provider networks. Because of its central role in the global healthcare and pharmaceutical ecosystem, the organization is entrusted with highly confidential data assets that extend far beyond standard commercial records. In 2026, official disclosures submitted to the Vermont Attorney General revealed that Amgen Inc. suffered a significant cybersecurity incident, compromising its network infrastructure and exposing sensitive individual data. While the precise vector of the intrusion continues to be analyzed, breaches affecting major biopharmaceutical and life sciences entities typically involve sophisticated cyberattacks such as unauthorized access to internal enterprise servers, targeted ransomware deployments, or compromises within deeply integrated third-party vendor supply chains. Given the interconnected nature of modern pharmaceutical operations, attackers frequently target vulnerabilities in digital file-transfer mechanisms, cloud storage environments, or administrative networks to infiltrate foundational corporate systems. The exposure resulting from this security failure threatens individuals whose personal and professional information was stored within the company's network. Depending on the exact systems accessed, the compromised data likely includes full names, dates of birth, Social Security numbers, confidential healthcare or clinical trial identifiers, banking or payroll details, and contact information. The compromise of such varied and sensitive records creates immediate, severe risks for affected victims. When Social Security numbers and personal identifiers are leaked alongside employment or healthcare context, victims face a substantially elevated risk of identity theft, fraudulent credit applications, unauthorized tax filings, and targeted financial scams that can take years to fully resolve. Under federal and state legal frameworks, including the Vermont Consumer Protection Act and applicable data protection standards, organizations like Amgen Inc. maintain a strict legal duty to implement and maintain reasonable cybersecurity measures to safeguard private information. These legal obligations require continuous system monitoring, robust encryption protocols, prompt patch management, and strict access controls to prevent unauthorized intrusion. The occurrence of a widespread data breach strongly indicates a failure in these security safeguards, suggesting that the enterprise may have fallen short of its legal obligations to protect confidential records from foreseeable cyber threats. Receiving a formal data breach notification letter from Amgen Inc. serves as official confirmation that your personal information was compromised due to corporate security negligence. Legally, the receipt of this notice establishes the concrete injury and standing necessary to participate in a class action lawsuit aimed at holding the company accountable. Affected individuals are not required to show out-of-pocket financial loss to qualify for legal relief. Our firm evaluates these data breach cases on a strict contingency fee basis, meaning you pay nothing and owe no attorney fees unless financial recovery is successfully secured on your behalf." Reviewing your accounts and credit for unfamiliar activity is a sensible precaution. Because this breach was recently disclosed, affected individuals may wish to review their options promptly.
Amgen Inc. was required under the Vermont Security Breach Notice Act to implement reasonable security measures to protect the personal information it collected. When those measures fail and personal data is exposed to unauthorized parties, the law provides remedies for affected individuals — regardless of whether those individuals have yet experienced fraud or identity theft as a direct result.
Amgen Inc. stands as one of the world's leading independent biotechnology innovators, dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics to patients suffering from serious illnesses. Operating at the cutting edge of life sciences, biopharmaceuticals, and clinical research, the enterprise collects and maintains vast repositories of deeply sensitive information. This operational footprint requires the collection of extensive proprietary research data, clinical trial participant records, detailed employee and personnel files, and intricate healthcare provider networks. Because of its central role in the global healthcare and pharmaceutical ecosystem, the organization is entrusted with highly confidential data assets that extend far beyond standard commercial records. In 2026, official disclosures submitted to the Vermont Attorney General revealed that Amgen Inc. suffered a significant cybersecurity incident, compromising its network infrastructure and exposing sensitive individual data. While the precise vector of the intrusion continues to be analyzed, breaches affecting major biopharmaceutical and life sciences entities typically involve sophisticated cyberattacks such as unauthorized access to internal enterprise servers, targeted ransomware deployments, or compromises within deeply integrated third-party vendor supply chains. Given the interconnected nature of modern pharmaceutical operations, attackers frequently target vulnerabilities in digital file-transfer mechanisms, cloud storage environments, or administrative networks to infiltrate foundational corporate systems. The exposure resulting from this security failure threatens individuals whose personal and professional information was stored within the company's network. Depending on the exact systems accessed, the compromised data likely includes full names, dates of birth, Social Security numbers, confidential healthcare or clinical trial identifiers, banking or payroll details, and contact information. The compromise of such varied and sensitive records creates immediate, severe risks for affected victims. When Social Security numbers and personal identifiers are leaked alongside employment or healthcare context, victims face a substantially elevated risk of identity theft, fraudulent credit applications, unauthorized tax filings, and targeted financial scams that can take years to fully resolve. Under federal and state legal frameworks, including the Vermont Consumer Protection Act and applicable data protection standards, organizations like Amgen Inc. maintain a strict legal duty to implement and maintain reasonable cybersecurity measures to safeguard private information. These legal obligations require continuous system monitoring, robust encryption protocols, prompt patch management, and strict access controls to prevent unauthorized intrusion. The occurrence of a widespread data breach strongly indicates a failure in these security safeguards, suggesting that the enterprise may have fallen short of its legal obligations to protect confidential records from foreseeable cyber threats. Receiving a formal data breach notification letter from Amgen Inc. serves as official confirmation that your personal information was compromised due to corporate security negligence. Legally, the receipt of this notice establishes the concrete injury and standing necessary to participate in a class action lawsuit aimed at holding the company accountable. Affected individuals are not required to show out-of-pocket financial loss to qualify for legal relief. Our firm evaluates these data breach cases on a strict contingency fee basis, meaning you pay nothing and owe no attorney fees unless financial recovery is successfully secured on your behalf.
Based on the data types reported in this filing, affected individuals face the following specific risks:
Your SSN is the master key to your identity. Once exposed, criminals can open new lines of credit, take out loans, or file taxes in your name.
Combined with a name and other leaked data, date of birth helps criminals pass identity verification questions at banks and government agencies.
Phone numbers exposed in breaches are used for SIM swapping attacks — hijacking your number to bypass two-factor authentication on financial accounts.
Under the Vermont Security Breach Notice Act, you may have a legal claim against Amgen Inc. if any of the following apply:
Applicable law: This breach was reported under the Vermont Security Breach Notice Act, which establishes your right to seek damages from Amgen Inc..
The hours spent responding to a data breach — canceling accounts, contacting credit bureaus, updating passwords, and investigating fraud — represent compensable economic harm in data breach litigation.
Once your SSN is exposed, protection becomes an ongoing expense. Plaintiffs in data breach settlements have recovered costs for credit freezes, identity protection subscriptions, and time spent dealing with fraudulent accounts — sometimes covering multiple years of exposure.
Several state data breach laws provide for statutory minimum damages — fixed amounts recoverable per affected individual regardless of actual loss. These provisions exist specifically to make legal action viable for victims who have not yet experienced direct harm.
No. Under Vermont Security Breach Notice Act and federal law, the unauthorized exposure of your personal data — regardless of whether it has been actively misused — can be sufficient grounds for a claim. The breach itself is the injury.
Nothing. The Law Office of David S. Harris handles data breach cases on contingency — you pay zero upfront and owe nothing unless compensation is recovered.
Immediately place a free credit freeze at all three bureaus (Equifax, Experian, TransUnion). A freeze blocks new accounts from being opened in your name. Then file a complaint with the FTC at IdentityTheft.gov and contact our office — SSN exposure is one of the most serious breach types.
State statutes of limitations for data breach claims typically run 2–4 years from the date of the breach or its discovery. Because this breach was recently disclosed, the window is open — but acting early preserves your options and strengthens the case.
Accepting free credit monitoring from Amgen Inc. does not waive your right to pursue legal action unless you signed a specific release waiving claims. In most cases, victims who accepted monitoring can still file.
Not necessarily. Many data breach victims are never notified directly. If your personal information was held by Amgen Inc. during the relevant period, you may still qualify even without receiving a letter. A free eligibility review can confirm your status.
Most data breach class actions resolve within 18 to 36 months, though timelines vary by court and complexity. Your participation requires minimal effort — typically completing a claim form. Our office handles all litigation; you are notified when a settlement is reached.
Received a notification letter from Amgen Inc.?
Read our dedicated guide — what the letter means and exactly what to do.
If you were affected by the Amgen Inc. data breach, you may be entitled to compensation. Submit your information below for a free attorney review — no obligation, no upfront cost.
This registry entry documents a notice associated with Amgen Inc. that was filed in VT on August 17, 2026. The filing describes Full Name, Date of Birth, Social Security Number.
Public filing source
View filing source →Amgen Inc. breach?
Free case review · No fee unless you win